DOI: https://doi.org/10.24959/cphj.20.1519

Quinolones (ATC-group J01M): the state of the pharmaceutical market, analysis of consumption in Ukraine and in some European countries in 2013-2018

T. O. Bahlai

Abstract


The synthesis of the first antibiotic of the Quinolone group took place in 1958. Since then, Quinolones are widely used in clinical practice around the world due to their wide antibacterial spectrum of action.

Aim. To study the pharmaceutical market of Ukraine of the Quinolone antibiotics group, as well as determine the volumes of their consumption in 2013-2018.

Materials and methods. The analysis of the assortment of antibiotics of the Quinolone group was carried out according to the WHO Collaborating Center by methodologies for statistical analysis of drugs and according to the State Register of Medicines of Ukraine. The consumption was calculated using a standardized ATC/DDD methodology recommended by the WHO.

Results. Eleven INNs of the Quinolone group antibiotics are presented at the pharmaceutical market of Ukraine, as well as 6 INNs of combinations with Quinolones. In 2018, 159 trade names (TNs) of Quinolones were registered in Ukraine; 40.25 % of them are of domestic production (64 TNs). The consumption of Quinolones for the study period increased from 1.77 DID in 2016 to 1.83 DID in 2018. In general, the ABD consumption in the countries of the European Union and the European Economic Area (EU/EEA) decreased during the study period from с 1.77 DID in 2013 to 1.5 DID in 2018.

Conclusions. Eleven INNs of Quinolone group antibiotics are presented at the pharmaceutical market of Ukraine, as well as 6 INNs of combinations with Quinolones presented by 159 TNs in 2018. The consumption of Quinolones increased over the study period from 1.77 DID in 2016 to 1.83 DID in 2018. Within 2013-2016 the consumption of Quinolone antibiotics in Ukraine was lower than in the EU/EEA, but in 2017 the consumption in Ukraine increased to 0.15 DID, and in 2018 the difference increased to 0.33 DID.

Keywords


quinolones; fluoroquinolones; antibacterial drugs; consumption; antibiotic resistance

References


Lack of new antibiotics threatens global efforts to contain drug-resistant infections. (2020). WHO News release. 17 January 2020. Geneva. Available at: https://www.who.int/news-room/detail/17-01-2020-lack-of-new-antibiotics-threatens-global-efforts-to-contain-drug-resistant-infections (date of access: 20.01.2020).

Carroll, G. (1963). Neggram (nalidixic Acid): A New Antimicrobial Chemotherapeutic Agent. Journal of Urology, 90(4), 476–480. https://doi.org/10.1016/s0022-5347(17)64441-0

Lesher, G. Y., Froelich, E. J., Gruett, M. D., Bailey, J. H., & Brundage, R. P. (1962). 1,8-Naphthyridine Derivatives. A New Class of Chemotherapeutic Agents. Journal of Medicinal and Pharmaceutical Chemistry, 5(5), 1063–1065. https://doi.org/10.1021/jm01240a021

Autio, S., Makela, P., & Sunila, R. (1966). Experience with Nalidixic Acid in the Treatment of Urinary Tract Infections of Children. Archives of Disease in Childhood, 41(218), 395–399. https://doi.org/10.1136/adc.41.218.395

Barton, N., Crowther, A. F., Hepworth, W., Richardson, N. D., Driver, G. W. (1960). New Quinolones and Therapeutic Compositions Containing Them. GB830832.

Pham, T., Ziora, Z. M., & Blaskovich, M. (2019). Quinolone antibiotics. MedChemComm, 10(10), 1719–1739. https://doi.org/10.1039/c9md00120d

King, D. E., Malone, R., & Lilley, S. H. (2000). New classification and update on the quinolone antibiotics. American family physician, 61(9), 2741–2748.

WHO Collaborating Centre for Drug Statistics Methodology. (n.d.). Available at: https://www.whocc.no/atc_ddd_index/ (date of access: 21.01.2020).

Naber, K. G., & Adam, D. (1998). Classification of fluoroquinolones. International Journal of Antimicrobial Agents, 10(4), 255–257. https://doi.org/10.1016/s0924-8579(98)00059-4

Makino, M. (1968). Hinyokika kiyo. Acta urologica Japonica, 14(6), 351–356.

Sharma, P. C., Jain, A., & Jain, S. (2009). Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects. Acta poloniae pharmaceutica, 66(6), 587–604.

Pham, T., Ziora, Z. M., & Blaskovich, M. (2019). Quinolone antibiotics. MedChemComm, 10(10), 1719–1739. https://doi.org/10.1039/c9md00120d

Derzhavnyi reiestr likarskykh zasobiv Ukrainy. (n.d.). Departament farmatsevtychnoi diialnosti, Derzhavnyi ekspertnyi tsentr Ministerstva okhorony zdorovia Ukrainy. Available at: http://www.drlz.com.ua (data zvernennia: 20.01.2020).

Systema doslidzhennia rynku likarskykh zasobiv «Farmstandart» kompanii «Morion». (n.d.). Available at: http://www.pharmstandart.com.ua (data zvernennia: 20.01.2020).

Morozov, A. M., Yakovlieva, L. V., Stepanenko, A. V., Zimenkovskyi, A. B., Parii, V. D., Dumenko, T. M., Matiashova, N. O., Adonkina, V. Yu. (2013). Vyvchennia spozhyvannia likarskykh zasobiv za anatomo-terapevtychno-khimichnoiu klasyfikatsiieiu ta vstanovlenymy dobovymy dozamy (ATC/DDD-metodolohiia): Metod. Rekomendatsii. Kyiv: NFaU, DETs MOZ Ukrainy, 32.

European Surveillance of Antimicrobial Consumption Network. Publications & data. Reports for (2015, 2016, 2017, 2018). Available at: https://www.ecdc.europa.eu/en/publications-data (date of access:01.02.2020).

Psaty, B. M. (2008). Clinical Trial Design and Selected Drug Safety Issues for Antibiotics Used to Treat Community‐Acquired Pneumonia. Clinical Infectious Diseases, 47(S3), S176–S179. https://doi.org/10.1086/591400

Owens, R. C., & Ambrose, P. G. (2000). Clinical use of the fluoroquinolones. Medical Clinics of North America, 84(6), 1447–1469. https://doi.org/10.1016/S0025-7125(05)70297-2


GOST Style Citations


1.    Lack of new antibiotics threatens global efforts to contain drug-resistant infections. – WHO News release. 17 January 2020. – Geneva. [Електронний ресурс]. – Режим доступу : https://www.who.int/news-room/detail/17-01-2020-lack-of-new-antibiotics-threatens-global-efforts-to-contain-drug-resistant-infections (date of access: 20.01.2020).

 

2.    Carroll, G. Neggram (nalidixic acid): a new antimicrobial chemotherapeutic agent / G. Carroll / The Journal of Urol. – 1963. – Vol. 90. – P. 476–478. https://doi.org/10.1016/s0022-5347(17)64441-0

 

3.    1,8-naphthyridine derivatives. A new class of chemotherapeutic agents / G. Y. Lesher, E. J. Froelich, M. D. Gruett et al. // J. of Medicinal and Pharmaceutical Chemistry. – 1962. – Vol. 91. – P. 1063–1065. https://doi.org/10.1021/jm01240a021

 

4.    Autio, S. Experience with Nalidixic Acid in the Treatment of Urinary Tract Infections of Children / S. Autio, P. Mäkelä, R. Sunila // Archives of Disease in Childhood. – 1966. – Vol. 41. – P. 395–399. https://doi.org/10.1136/adc.41.218.395 

 

5.    New Quinolones and Therapeutic Compositions Containing Them / N. Barton, A. F. Crowther, W. Hepworth et al. // GB830832. – 1960.

 

6.    Pham, T. Quinolone antibiotics / T. Pham, Z. M. Ziora, M. Blaskovich // MedChemComm. – 2019. – Vol. 10 (10). – P. 1719–1739. https://doi.org/10.1039/c9md00120d

 

7.    King, D. E. New classification and update on the quinolone antibiotics / D. E. King, R. Malone, S. H. Lilley // American Family Physician. – 2000. – Vol. 61 (9). – P. 2741–2748.

 

8.    Центр співпраці ВООЗ з методології статистичного аналізу лікарських засобів. WHO Collaborating Centre for Drug Statistics Methodology. [Електронний ресурс]. – Режим доступу : https://www.whocc.no/atc_ddd_index/ (дата звернення: 21.01.2020).

 

9.    Naber, K. Classification of fluoroquinolones / K. Naber, D. Adam // Int. J. Antimicrob. Agents. – 1998. – Vol. 10. – P. 255–257 https://doi.org/10.1016/S0924-8579(98)00059-4

 

10.  Makino, M. Hinyokika kiyo / M. Makino // Acta Urologica Japonica. – 1968. – Vol. 14 (6). – P. 351–356.

 

11.  Sharma, P. C. Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects / P. C. Sharma, A. Jain, S. Jain // Acta Poloniae Pharmaceutica. – 2009. – Vol. 66 (6). – P. 587–604.

 

12.  Pham, T. Quinolone antibiotics / T. Pham, Z. M. Ziora, M. Blaskovich // MedChemComm. – 2019. – Vol. 10 (10). – P. 1719–1739. https://doi.org/10.1039/c9md00120d

 

13.  Державний реєстр лікарських засобів України. Департамент фармацевтичної діяльності, Державний експертний центр Міністерства охорони здоров’я України. [Електронний ресурс]. – Режим доступу : http://www.drlz.com.ua (дата звернення: 20.01.2020).

 

14.  Система дослідження ринку лікарських засобів «Фармстандарт» компанії «Моріон». [Електронний ресурс]. – Режим доступу : http://www.pharmstandart.com.ua (дата звернення: 20.01.2020).

 

15.  Вивчення споживання лікарських засобів за анатомо-терапевтично-хімічною класифікацією та встановленими добовими дозами (ATC/DDD-методологія) : метод. рек. / А. М. Морозов, Л. В. Яковлєва, А. В. Степаненко та ін. – К. : НФаУ, ДЕЦ МОЗ України, 2013. – 32 с.

 

16.  European Surveillance of Antimicrobial Consumption Network / Publications & data. Reports for 2015, 2016, 2017, 2018. [Електронний ресурс]. – Режим доступу : https://www.ecdc.europa.eu/en/publications-data (date of access:01.02.2020).

 

17.  Psaty, B. M. (2008). Clinical trial design and selected drug safety issues for antibiotics used to treat community-acquired pneumonia / B. M. Psaty // Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. – 2008. – Vol. 47, Suppl 3. – P. 176–179. https://doi.org/10.1086/591400

 

18.  Owens, R. C. Clinical use of the fluoroquinolones / R. C. Owens, P. G. Ambrose // Medical Clinics of North America. – 2000. – Vol. 84, Iss. 6. – P. 1447–1469. https://doi.org/10.1016/S0025-7125(05)70297-2





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Clin. pharm.

ISSN 2518-1572 (Online), ISSN 1562-725X (Print)